1H NMR spectroscopy for the prediction of therapeutic outcome in patients with fulminant hepatic failure

Varsha Saxena, Ashish Gupta, G. A Nagana Gowda, Rajan Saxena, S. K. Yachha, C. L. Khetrapal

Research output: Contribution to journalArticle

Abstract

A high-resolution 1H NMR study of serum and urine of fulminant hepatic failure patients (n = 22) [surviving (n = 12) and non-surviving (n = 10)] is reported. Glutamine in serum and urine glutamine:creatinine ratio were higher in non-surviving patients compared with surviving patients [serum glutamine, 3.08 (1.69-7.11) vs 0.56 (0.34-0.99) mM, median and range; p = 0.0001 and urine glutamine:creatinine ratio, 1.72 (0.24-7.76) vs 0.39 (0.1-0.84), p = 0.1], and urine urea:creatinine ratio was higher in surviving patients compared with non-surviving patients [10.83 (0.2-22.6) vs 2.09 (0.96-4.0), P = 0.002]. On the other hand, no significant differences were found in the conventionally employed clinical parameters such as serum alanylaminotransferase, aspartylaminotransferase and bilirubin except prothrombin time (p = 0.02). The difference in serum glutamine and urine urea was significant in the two categories of patients and distinctly different values of serum glutamine for both the categories of patients correctly predicted the outcome. These results promise immense potential for NMR spectroscopy in rapidly deciding on the need for advanced therapeutic intervention such as artificial liver support or emergency liver transplantation in FHF.

Original languageEnglish (US)
Pages (from-to)521-526
Number of pages6
JournalNMR in Biomedicine
Volume19
Issue number5
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Acute Liver Failure
Glutamine
Nuclear magnetic resonance spectroscopy
Magnetic Resonance Spectroscopy
Urine
Serum
Creatinine
Liver
Urea
Therapeutics
Artificial Liver
Prothrombin
Bilirubin
Prothrombin Time
Proton Magnetic Resonance Spectroscopy
Liver Transplantation
Nuclear magnetic resonance
Emergencies

Keywords

  • H NMR
  • Fulminant hepatic failure
  • Glutamine
  • Liver disease
  • Serum
  • urea
  • Urine

ASJC Scopus subject areas

  • Spectroscopy
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Biophysics

Cite this

Saxena, V., Gupta, A., Gowda, G. A. N., Saxena, R., Yachha, S. K., & Khetrapal, C. L. (2006). 1H NMR spectroscopy for the prediction of therapeutic outcome in patients with fulminant hepatic failure. NMR in Biomedicine, 19(5), 521-526. https://doi.org/10.1002/nbm.1034

1H NMR spectroscopy for the prediction of therapeutic outcome in patients with fulminant hepatic failure. / Saxena, Varsha; Gupta, Ashish; Gowda, G. A Nagana; Saxena, Rajan; Yachha, S. K.; Khetrapal, C. L.

In: NMR in Biomedicine, Vol. 19, No. 5, 08.2006, p. 521-526.

Research output: Contribution to journalArticle

Saxena, V, Gupta, A, Gowda, GAN, Saxena, R, Yachha, SK & Khetrapal, CL 2006, '1H NMR spectroscopy for the prediction of therapeutic outcome in patients with fulminant hepatic failure', NMR in Biomedicine, vol. 19, no. 5, pp. 521-526. https://doi.org/10.1002/nbm.1034
Saxena, Varsha ; Gupta, Ashish ; Gowda, G. A Nagana ; Saxena, Rajan ; Yachha, S. K. ; Khetrapal, C. L. / 1H NMR spectroscopy for the prediction of therapeutic outcome in patients with fulminant hepatic failure. In: NMR in Biomedicine. 2006 ; Vol. 19, No. 5. pp. 521-526.
@article{6f9a04304ad44809ad33c0387a6bd5c3,
title = "1H NMR spectroscopy for the prediction of therapeutic outcome in patients with fulminant hepatic failure",
abstract = "A high-resolution 1H NMR study of serum and urine of fulminant hepatic failure patients (n = 22) [surviving (n = 12) and non-surviving (n = 10)] is reported. Glutamine in serum and urine glutamine:creatinine ratio were higher in non-surviving patients compared with surviving patients [serum glutamine, 3.08 (1.69-7.11) vs 0.56 (0.34-0.99) mM, median and range; p = 0.0001 and urine glutamine:creatinine ratio, 1.72 (0.24-7.76) vs 0.39 (0.1-0.84), p = 0.1], and urine urea:creatinine ratio was higher in surviving patients compared with non-surviving patients [10.83 (0.2-22.6) vs 2.09 (0.96-4.0), P = 0.002]. On the other hand, no significant differences were found in the conventionally employed clinical parameters such as serum alanylaminotransferase, aspartylaminotransferase and bilirubin except prothrombin time (p = 0.02). The difference in serum glutamine and urine urea was significant in the two categories of patients and distinctly different values of serum glutamine for both the categories of patients correctly predicted the outcome. These results promise immense potential for NMR spectroscopy in rapidly deciding on the need for advanced therapeutic intervention such as artificial liver support or emergency liver transplantation in FHF.",
keywords = "H NMR, Fulminant hepatic failure, Glutamine, Liver disease, Serum, urea, Urine",
author = "Varsha Saxena and Ashish Gupta and Gowda, {G. A Nagana} and Rajan Saxena and Yachha, {S. K.} and Khetrapal, {C. L.}",
year = "2006",
month = "8",
doi = "10.1002/nbm.1034",
language = "English (US)",
volume = "19",
pages = "521--526",
journal = "NMR in Biomedicine",
issn = "0952-3480",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - 1H NMR spectroscopy for the prediction of therapeutic outcome in patients with fulminant hepatic failure

AU - Saxena, Varsha

AU - Gupta, Ashish

AU - Gowda, G. A Nagana

AU - Saxena, Rajan

AU - Yachha, S. K.

AU - Khetrapal, C. L.

PY - 2006/8

Y1 - 2006/8

N2 - A high-resolution 1H NMR study of serum and urine of fulminant hepatic failure patients (n = 22) [surviving (n = 12) and non-surviving (n = 10)] is reported. Glutamine in serum and urine glutamine:creatinine ratio were higher in non-surviving patients compared with surviving patients [serum glutamine, 3.08 (1.69-7.11) vs 0.56 (0.34-0.99) mM, median and range; p = 0.0001 and urine glutamine:creatinine ratio, 1.72 (0.24-7.76) vs 0.39 (0.1-0.84), p = 0.1], and urine urea:creatinine ratio was higher in surviving patients compared with non-surviving patients [10.83 (0.2-22.6) vs 2.09 (0.96-4.0), P = 0.002]. On the other hand, no significant differences were found in the conventionally employed clinical parameters such as serum alanylaminotransferase, aspartylaminotransferase and bilirubin except prothrombin time (p = 0.02). The difference in serum glutamine and urine urea was significant in the two categories of patients and distinctly different values of serum glutamine for both the categories of patients correctly predicted the outcome. These results promise immense potential for NMR spectroscopy in rapidly deciding on the need for advanced therapeutic intervention such as artificial liver support or emergency liver transplantation in FHF.

AB - A high-resolution 1H NMR study of serum and urine of fulminant hepatic failure patients (n = 22) [surviving (n = 12) and non-surviving (n = 10)] is reported. Glutamine in serum and urine glutamine:creatinine ratio were higher in non-surviving patients compared with surviving patients [serum glutamine, 3.08 (1.69-7.11) vs 0.56 (0.34-0.99) mM, median and range; p = 0.0001 and urine glutamine:creatinine ratio, 1.72 (0.24-7.76) vs 0.39 (0.1-0.84), p = 0.1], and urine urea:creatinine ratio was higher in surviving patients compared with non-surviving patients [10.83 (0.2-22.6) vs 2.09 (0.96-4.0), P = 0.002]. On the other hand, no significant differences were found in the conventionally employed clinical parameters such as serum alanylaminotransferase, aspartylaminotransferase and bilirubin except prothrombin time (p = 0.02). The difference in serum glutamine and urine urea was significant in the two categories of patients and distinctly different values of serum glutamine for both the categories of patients correctly predicted the outcome. These results promise immense potential for NMR spectroscopy in rapidly deciding on the need for advanced therapeutic intervention such as artificial liver support or emergency liver transplantation in FHF.

KW - H NMR

KW - Fulminant hepatic failure

KW - Glutamine

KW - Liver disease

KW - Serum

KW - urea

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=33747343156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747343156&partnerID=8YFLogxK

U2 - 10.1002/nbm.1034

DO - 10.1002/nbm.1034

M3 - Article

C2 - 16598697

AN - SCOPUS:33747343156

VL - 19

SP - 521

EP - 526

JO - NMR in Biomedicine

JF - NMR in Biomedicine

SN - 0952-3480

IS - 5

ER -